Economic analyses of phase III cooperative cancer group clinical trials: are they feasible?

Cancer Investigation
C L BennettJ M Rowe

Abstract

Both economic and clinical evaluations of new pharmaceutical agents are important to physicians who practice in the current health care environment. While cooperative cancer groups carry out large-scale phase III clinical evaluations of these agents, few cooperative group studies incorporate economic analyses because of concerns over overburdening of data management, investigators, and statistical center personnel. In this study, we describe the results and operational considerations of one of the first completed economic analyses of a phase III cooperative group trial of the Eastern Cooperative Oncology Group (ECOG). We developed an economic model estimating economic benefits of yeast-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy for adult patients (56-70 years) with acute myelogenous leukemia. Clinical data were based on prospectively collected information from a recently reported double-blind phase III multi-institutional study carried out by ECOG. Retrospective economic data were obtained from financial information systems at our hospital, one of the study sites. The cost-minimization analyses were based on the perspective of a third-party payer. Indirect costs related to loss of earni...Continue Reading

References

Jun 22, 1995·The New England Journal of Medicine·T J Hamblin
Sep 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C L BennettH B Niell
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Jan 1, 1994·Cancer Investigation·C L BennettS Gulati

❮ Previous
Next ❯

Citations

Aug 8, 2001·Current Oncology Reports·G H Lyman
Mar 16, 2000·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·W K EvansA Smith
Feb 19, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·G H LymanL Balducci
Oct 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D H SmithC L Bennett
May 5, 1999·Current Opinion in Hematology·G H Lyman, L Balducci
Apr 16, 2002·Current Opinion in Hematology·Gary H LymanLodovico Balducci
Sep 21, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ann M HendricksJames A Talcott
May 18, 2010·International Journal of Radiation Oncology, Biology, Physics·Andre KonskiDeborah Watkins-Bruner
May 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Johanna N H Timmer-BonteVivianne C G Tjan-Heijnen
Jun 3, 1999·PharmacoEconomics·V JønssonS Kaasa
Nov 9, 2006·Health Affairs·Gail R Wilensky
Jan 30, 2004·Cancer Control : Journal of the Moffitt Cancer Center·James J Dignam
Oct 14, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H OzerUNKNOWN American Society of Clinical Oncology

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.